Company intelligence / Profile preview
Immunimed
United Statesimmunimed.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
IM‑01, an egg-derived polyclonal antibody targeting C. difficile toxins, has been evaluated in a Phase 2 clinical trial for mild-to-moderate Clostridium difficile infection. The study assessed resolution of diarrhea and recurrence rates; detailed results are not publicly available as of the latest update[2].
- Therapeutic areas
- Infectious Diseases
- Modalities
- Polyclonal antibody therapyAntibody (general)
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Immunimed.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Immunimed.